Harrow, Inc. (HROW)
(Real Time Quote from BATS)
$37.62 USD
+0.57 (1.54%)
Updated Aug 15, 2024 10:56 AM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HROW 37.62 +0.57(1.54%)
Will HROW be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HROW based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HROW
Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates
Harrow (HROW) Is a Great Choice for 'Trend' Investors, Here's Why
HROW: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
New Strong Sell Stocks for November 14th
Other News for HROW
Private Capital's Strategic Moves Highlight Ligand Pharmaceuticals in Q2 2024
Commit To Purchase Harrow At $27, Earn 22.2% Annualized Using Options
Harrow price target raised by $15 at Craig-Hallum, here's why
Harrow price target raised by $21 at B. Riley, here's why
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Certara (CERT) and Harrow Health (HROW)